Pyoderma gangrenosum
Pyoderma gangrenosum je redka vnetna kožna bolezen, pri kateri boleče pustule ali vozliči postanejo razjede, ki postopoma rastejo. Pyoderma gangrenosum ni nalezljiv. Zdravljenje lahko vključuje kortikosteroide, ciklosporin ali različna monoklonska protitelesa. Čeprav lahko prizadene ljudi katere koli starosti, večinoma prizadene ljudi v 40. in 50. letih.
☆ V rezultatih raziskave Stiftung Warentest iz Nemčije leta 2022 je bilo zadovoljstvo potrošnikov z ModelDermom le nekoliko nižje kot s plačanimi telemedicinskimi svetovanji.
Na nogi osebe z ulceroznim kolitisom.
References
Pyoderma gangrenosum je redka kožna bolezen, ki povzroča boleče razjede z rdečimi ali škrlatnimi robovi. Klasificirana je kot vnetna bolezen in je del skupine, imenovane nevtrofilne dermatoze. Vzrok za pyoderma gangrenosum je zapleten in vključuje težave s prirojeno in adaptivno imunostjo pri ljudeh, ki so genetsko nagnjeni. Nedavno so se raziskovalci osredotočili na lasni mešiček kot možno izhodišče bolezni.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum je redka kožna bolezen, ki povzroča izjemno boleče razjede. Čeprav ne razumemo povsem njegovega vzroka, vemo, da vključuje povečano aktivnost določenih imunskih celic. Zdravljenje bolezni še vedno ni enostavno. Imamo različna zdravila, ki zavirajo imunski sistem ali spreminjajo njegovo delovanje. Poleg tega se osredotočamo tudi na zdravljenje ran in obvladovanje bolečin. Kortikosteroidi in ciklosporin so pogosto prva izbira za zdravljenje, vendar je bilo v zadnjem času več raziskav o uporabi bioloških terapij, kot so zaviralci TNF-α. Ta biološka zdravila imajo vedno večjo prednost, zlasti pri bolnikih z drugimi vnetnimi stanji, in se uporabljajo v zgodnejših fazah bolezni.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
